



NOV 1 2004

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mike Sammon, Ph.D.
Senior Director of Research and Development
MediSISS, Inc.
2747 SW 6th Street
Redmond, Oregon 97756

Re: K030598 - Supplemental Validation Submission
Trade/Device Name: Ethicon, CS-14C, LCS-C5 (see enclosed list)
Regulation Name: Ultrasonic Surgical Instruments
Regulatory Class: Unclassified
Product Code: NLQ
Dated: December 30, 2003
Received: December 31, 2003

Dear Dr. Sammon:

The above-referenced premarket notification (510(k)) was cleared by the Office of Device Evaluation (ODE) on January 23, 2004. We have received your supplemental validation data as required for reprocessed single-use devices by the Medical Device User Fee and Modernization Act of 2002. After reviewing your supplemental validation data, we have determined the devices listed in the enclosure accompanying this letter are substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market these devices, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your devices are classified (see above) into either class II (Special Controls) or class III (PMA) they may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your devices in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your devices comply with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's applicable requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


Page 2 - Mike Sammon, Ph.D.

The FDA finding of substantial equivalence of your devices to legally marketed predicate devices results in classification for your devices and thus, permits you to legally market the devices. This letter will allow you to continue marketing the devices listed in the enclosure accompanying this letter.

If you desire specific advice for your devices on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at 240-276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

for



Celia M. Witten, M.D., Ph.D.

Director

Division of General, Restorative, and
Restorative Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Reprocessed Ultrasonic Surgical Instruments found to be Substantially Equivalent:

Ethicon,	CS-14C
Ethicon,	LCS-C5

Prescription Use ✓
Use _____
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Steph Pluchis
(Division Sign-Off)

**Division of General, Restorative,
and Neurological Devices**

Page 1 of 1

510(k) Number K030598

**Summary of Safety and Effectiveness
for the
Reprocessed Ultrasonic Instruments**

submitted by

SISS d.b.a. MediSISS, Inc.
P.O. 2060
723 Curtis Court
Sisters, OR 97759
Phone: (800)-860-9482
Fax: (541) 549-4527
Email: mabarker@medisiss.com

Contact Person: Mary Ann Barker
Device Trade Names: MediSISS™ Reprocessed Ultrasonic Surgical Instruments
Common Names: Reprocessed Ultrasonic Surgical Instruments
Classification Names: Instrument, Ultrasonic Surgical, Unclassified; Product Code: LFL; Regulatory Class: II

Identification of a Legally Marketed Predicate Device

The SISS d.b.a. MediSISS™ Reprocessed Ultrasonic Surgical Instruments are substantially equivalent to the devices as listed below:

Company	510(k) #
Ethicon Endo-Surgery (Ultracision)	K980099, K993054, and K010898
U.S.Surgical	K971861
Olympus Optical	K972114

They are also similar to the Reprocessed Ultrasonic Surgical Instruments reprocessed by SterilMed Corporation and legally marketed and distributed pursuant to *Reprocessed Harmonic Scalpels* 510(k) K012571 and likewise, Vanguard's 510(k) 022780 *Vanguard Reprocessed Ultrasonic Scalpel*.

Device Description

Reprocessed Ultrasonic Surgical Instruments consist of hand-manipulated devices, with or without rotation capability, with or without cutting ability.

The handpiece handles are connected to the distal end-effector by a narrow-diameter metal barrel or shaft. The distal end of the device consists of a scalpel with a variety of end configurations including Flat, Cutting, and Blunt or a combination of the same. The devices are designed to be inserted through an appropriately sized trocar sleeve or cannula or used to be used in open surgery. The end-effectors are usually operated by the handpiece handles. The handles may be designed to be suppressed and released to activate the instruments end-effector. Similarly the handle may incorporate a button or switch to activate the end-effectors.

The device's shaft may be designed to (depending on the device model and type) be rotated (up to 360°) either direction (by manipulating controls located on the handle.)

Intended Use

The SISS d.b.a. MediSISS™ Reprocessed Ultrasonic Surgical Instruments are intended for soft tissue incisions when bleeding control and minimal thermal injury are desired. The instruments can be used as an adjunct to or substitute for electrosurgery, lasers, and steel instruments. The instruments are used in general, pediatric, thoracic, gynecologic, urologic, and other open and endoscopic surgeries for the transection, dissection, and coagulation of tissue(s).

Summary of Technological Characteristics

The intended use and technological features of the reprocessed devices do not differ from the legally marketed predicate device(s). Both the reprocessed devices(s) and the predicate device(s) have the same materials and product design. There are no changes to the claims, intended use, clinical applications, patient populations, performance specifications, or methods of operation. The technological characteristics of the Reprocessed Ultrasonic Surgical Instruments are the same as those of the legally marketed predicate devices. In addition the SISS d.b.a. MediSISS™ manufacturing process includes 100 % visual and mechanical testing of all products prior to packaging, labeling, and sterilization.

Summary of Performance Data

The SISS d.b.a. MediSISS™ Reprocessed Ultrasonic Surgical Instruments comply with the following standards, practices, and guidance's:

Sterilization Validation and EO Residuals:

- ANSI/AAMI/ISO 11135-1994, *Medical Devices—Validation and Routine Control of Ethylene Oxide Sterilization*

- ANS/AAMI/ISO 10993-7:1995, *Biological Evaluation of Medical Devices—Part 7: Ethylene oxide sterilization residual.*

Cleaning Validation:

- AAMI RDS0TIR No. 12-1994. *Designing, Testing, and Labeling Reusable Medical Devices for Reprocessing in Health Care Facilities: A guide for Device Manufacturers.* Association for the Advancement of Medical Instrumentation, Arlington, VA. Food and Drug Administration. 1996.
- *Labeling Reusable Medical Devices for Reprocessing in Health Care Facilities: FDA Reviewer Guidance, Office of Device Evaluation.* FDA, Washington, D.C.

Cleaning, sterilization, packaging validations, and visual/mechanical testing demonstrate that the devices are equivalent and continue to be safe and effective for their intended use.

SISS d.b.a. MediSISS™ Reprocessed Ultrasonic Surgical Instruments undergo mechanical testing to demonstrate that the parts do not change in function. Process validation testing was done to validate the cleaning and sterilization procedures as well as the device's packaging.

Conclusion

Since the SISS d.b.a. MediSISS™ Reprocessed Ultrasonic Surgical Instruments meet the requirements of the stated standards and embody technological characteristics identical to the predicate device, we believe the device is safe and effective and performs as well as or better than the predicate device. The SISS d.b.a. MediSISS™ Reprocessed Ultrasonic Surgical Instruments will be reprocessed per specifications, good manufacturing practices, and QSR (Quality System Regulations) that ensure the device is safe and effective for its intended use.

In Accordance with the Federal Food, Drug, and cosmetic Act, 21 CFR Part 807, and based on the 510(k) "Substantial Equivalence" Decision Making Process Chart and the information provided in this premarket notification, SISS d.b.a. MediSISS™ concludes that the device(s)(Reprocessed Ultrasonic Instruments) are safe, effective, and substantially equivalent to the predicate devices as described herein.

This conclusion is based upon the SISS d.b.a. MediSISS™ Reprocessed Ultrasonic Surgical Instruments similarities in functional design, materials, indications for use, and methods of construction to the predicate devices.